Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Our R&D Priorities, Our Challenges, and How The Hive Helps Us Overcome Them
Posted on January 17th, 2017 by Ph.D. Tom Wickham in Pharma R&D
In pursuit of our research efforts at Rubius Therapuetics, our key priorities are to develop our technology platform capability, generate data that broadly supports its application in key therapeutic areas, and advance our most promising concepts & leads toward clinical development. We’re confident that our innovative technology, talented people, and strong financial backing will enable us to meet these goals. At the same time, however, we also have to acknowledge that there will be some obstacles to overcome as we work to make these priorities into realities.
A big R&D challenge for a small company developing a platform technology that can be broadly applied across multiple disease areas is the ability to rapidly get up to speed on different disease areas and other technical areas critical toward improving the technology. This includes understanding the science and biology as well as the IP, clinical, and commercial landscapes. But that’s what is great about being a part of the The Hive. Hive participation has been an amazing resource in support of our effort to address this challenge.
Let me give you a few examples:
With ScienceDirect, we can rapidly find good review papers that allow us to get up to speed in any technical or therapeutic area as we look for new ways to interrogate fundamental biology and pathophysiology (particularly in areas where there are few or no approved treatments). What’s nice is that the papers are direct access, so no need to put in an order and wait for it to arrive. This accelerates our ability to rapidly get to the right information.
Because the Rubius technology has the potential to outperform approved drugs in many areas, through PharmaPendium we can quickly find the relevant comparative data. This might include key safety and efficacy clinical data from registration trials, toxicology, PK, or preclinical models. We have a few leads we’re developing where this information was key.
Finally, we’ve also been exploring Scopus and just used it at the American Society of Hematology (ASH) conference to find all the key papers from one of the speakers, based on citations. So all three of those tools have been particularly useful to us in very specific ways. In fact, we keep the ScienceDirect, Scopus, and PharmaPendium sites as bookmarks on the browser, and then they’re always right there when we want them!
Follow The Hive to find out more.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Ph.D. Tom Wickham
Vice President Research and Development at Rubius Therapeutics
- PharmaPendium and ExactCure review 20 approved drugs for COVID-19 therapies
- Rare disease research: grey literature is the new knowledge currency
- Dedication to science drives a 20-year relationship between an information expert and a distinguished researcher
- PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator
- FDA collaborates with Elsevier on drug-induced liver injury (DILI) tool